MDT-AP-2917
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 2
- sex
- M
- new_clusters
- C3
- umap1_2d
- 6.003909065
- umap2_2d
- 4.104473706
- umap1_3d
- 2.872638403
- umap2_3d
- -2.165823994
- umap3_3d
- -2.238835013
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.340
- PROTEIN_SECRETION+0.330
- G2M_CHECKPOINT+0.310
- DNA_REPAIR+0.280
- MYC_TARGETS_V1+0.270
- SPERMATOGENESIS+0.240
- MITOTIC_SPINDLE+0.230
- MYC_TARGETS_V2+0.130
- HEME_METABOLISM+0.100
- PANCREAS_BETA_CELLS+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- INFLAMMATORY_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- INTERFERON_GAMMA_RESPONSE-0.450
- TNFA_SIGNALING_VIA_NFKB-0.440
- HYPOXIA-0.420
- ANGIOGENESIS-0.410
- MYOGENESIS-0.410
- ALLOGRAFT_REJECTION-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
0 twins match this tumor's tissue · 10 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Z7PKVY9J | medulloblastoma | — | 0.964 |
| 2 | BS_KYF0Q0E7 | medulloblastoma | — | 0.963 |
| 3 | BS_K74PZET7 | medulloblastoma | — | 0.957 |
| 4 | BS_JFB984RG | medulloblastoma | — | 0.955 |
| 5 | BS_DFWFBYSN | medulloblastoma | — | 0.955 |
| 6 | BS_4CP4T22V | medulloblastoma | — | 0.953 |
| 7 | BS_HF3RNN2T | medulloblastoma | — | 0.952 |
| 8 | BS_H4B5Y6S0 | medulloblastoma | — | 0.952 |
| 9 | BS_GNV89A5P | medulloblastoma | — | 0.952 |
| 10 | BS_J8G4SH4Z | medulloblastoma | — | 0.950 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.040 | Inavolisib | — uncovered |